Materiality

In accordance with the corporate philosophy of “contributing to the healthier lives of people around the world through the creation of pharmaceuticals,” the Mitsubishi Tanabe Pharma Group believes that its ability to survive and grow depends on the provision of social value and a contribution to the achievement of a sustainable society through the Group’s business activities. To clarify that idea and reinforce our initiatives, we have designated material issues that we need to address as materiality. The Group has positioned these material issues as an important part of its decision-making process, and on that basis, the Group is implementing its business activities.

Process of Designating Material Issues

Step 1: Identify social issues that need to be considered

In designating material issues, the Group considered not only international guidelines and GRI standards but also SASB*1 pharmaceutical industry evaluation standards, ATM index*2 evaluation items, and others. In this way, social issues that need to be considered were identified in a comprehensive manner.

  • *1Sustainability Accounting Standards Board. An NPO based in the U.S. that sets and discloses sustainability evaluation standards by industry.
  • *2Access to Medicine Index. An index that analyzes and ranks 20 of the world's top pharmaceutical companies on how they make medicines more accessible. Implemented by the Access to Medicine Foundation, an NPO based in the Netherlands.

Step 2: Prioritize social issues

For the social issues identified in step 1, their importance for the Group was evaluated with consideration for such factors as the Group’s values and major policies, strategies and specific activity objectives, and risk-related information.
In addition, to evaluate the importance of these issues for stakeholders, we analyzed and organized items that are considered to be important by evaluation institutions that work to promote responsible investing on behalf of external stakeholders. From these two perspectives, we created a materiality map and narrowed down the issues to those with high priority.

Step 3: Confirm appropriateness and designate material issues

We designated the material issues after the validity of the materiality map was confirmed through consultation with experts from inside and outside the Company. For the seven material issues, we organized and confirmed their relevance in regard to major initiatives, the SDGs, the Group’s Code of Conduct, and theMOS indices of KAITEKI upheld by the Mitsubishi Chemical Holdings Corporation (MCHC) Group, of which Mitsubishi Tanabe Pharma is a member.

Material Issues

The table of material Issues, major Initiatives/results, Code of Conduct and related MOS Indices [PDF:122KB]

For further information about MOS Indices, please see the MCHC website.

Material Issues and Major Initiatives

In order to understand the status of the initiatives to material issues and further improve them, we set monitoring indicators and verify initiatives each fiscal year.

① Pharmaceuticals and healthcare services with differentiated value

  • 3 GOOD HEALTH AND WELL-BEING
  • 9 INDUSTRY,INNOVATION AND INFRASTRUCTURE
Major Initiatives and FY2018 Results (Region)
Creating new drugs, adding indications, changing dosage and administration, adding formulations, and improving products. Number of approvals (last 5 years) 23 (Global)
Number of product improvements
(last 5 years)
13 (Global)
Awards received for drug discovery
(total since 2007 merger)
18 (Global)
Number of vaccines shipped 17 million (Japan)
Number of patients using orphan*3 drugs provided by MTPC 100,000 (Global)
  • *3Medicines for diseases that are said to be intractable disease for which there are few patients and for which no cure has been established.

② Reliable products and sustainable supply

  • 3 GOOD HEALTH AND WELL-BEING
  • 12 RESPONSIBLE CONSUMPTION AND PRODUCTION
Major Initiatives and FY2018 Results (Region)
Building systems for a sustainable supply of reliable pharmaceuticals. The rate of complaints attributed to manufacturing process at group manufacturing plants 1ppm*4 (Global)
Satisfaction rating of responses to customer complaints 92.4% (Japan)
  • *41ppm=0.0001%

③ Appropriate use of products

  • 3 GOOD HEALTH AND WELL-BEING
  • 12 RESPONSIBLE CONSUMPTION AND PRODUCTION
Major Initiatives and FY2018 Results (Region)
Establishing a drug consultation center, collecting safety information, and providing information related to the appropriate use of products. Number of external presentations on clinical research (papers/academic conferences, etc.) 56 (Global)
Instances of safety information collected by MRs 7,419 (Japan)

④ Ethics, fairness and sincerity in business practices

  • 12 RESPONSIBLE CONSUMPTION AND PRODUCTION
  • 16 PEACE,JUSTICE AND STRONG INSTITUTIONS
Major Initiatives and FY2018 Results (Region)
Working to cultivate an awareness of compliance issues, establishing and observing a variety of policies, and establishing hotlines related to compliance and harassment. Compliance training participation rate 97.7% (Japan)
Employee compliance awareness
(Perfect score: 5 points)
4.34 points (Japan)

⑤ Stakeholder engagement

  • 12 RESPONSIBLE CONSUMPTION AND PRODUCTION
Major Initiatives and FY2018 Results (Region)
Implementing timely, appropriate information disclosure, implementing dialogue with stakeholders including investors and employees. Number of briefings and interviews of investors 198 (Global)
Employee understanding of management
(Perfect score: 5 points)
3.68 points (Japan)
Number of next-generation educational support activities
(visiting lectures, company visits, etc.)
10 (Japan)

⑥ Employee health, diversity and inclusion

  • 3 GOOD HEALTH AND WELL-BEING
  • 5 GENDER EQUALITY
  • 8 DECENT WORK AND ECONOMIC GROWTH
Major Initiatives and FY2018 Results (Region)
Taking steps to establish a work environment that enables all employees to participate actively, including promotion of health management; maternity leave, childcare leave, and nursing-care leave; and initiatives for LGBT employees. Total working hours
(per employee, per month)
153.9 hours (Japan)
Usage rate of paid vacation days 68% (Japan)
Smoking rate 19.8% (Japan)
Employee awareness of diversity
(Perfect score: 5 points)
3.72 points (Japan)
Percentage of women in managerial positions 20.2% (Global)
Number of employee nationalities 29 (Global)

⑦ Social contribution activities for health

  • 3 GOOD HEALTH AND WELL-BEING
  • 9 INDUSTRY,INNOVATION AND INFRASTRUCTURE
  • 17 PARTNERSHIPS FOR THE GOALS
Major Initiatives and FY2018 Results (Region)
Providing support for patient organizations and research, providing information related to diseases, the provision of vaccines in developing countries, and the GHIT Fund. Number of visitors to health support websites 7.29 million (Global)
Rate of employee participation in social contribution activities 42.3% (Japan)
Number of organizations supported by Tenohira Partnership Program
(total since start of grant in FY2013)
91 (Japan)
Number of supports provided by health contributing programs in developing countries 12,236 meals,
vaccine 14,500 doses
(Japan)

The table of material Issues, major Initiatives/results, Code of Conduct and related MOS Indices [PDF:122KB]

For further information about MOS Indices, please see the MCHC website.